

Peptide Therapeutics Market Report by Type (Innovative, Generic), Type of Manufacturer (Outsourced, In-House), Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, Hybrid Technology), Routes of Administration (Parenteral, Oral, and Others), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Others), and Region 2023-2028

Market Report | 2023-11-24 | 149 pages | IMARC Group

AVAILABLE LICENSES:

- Electronic (PDF) Single User \$2499.00
- Five User Licence \$3499.00
- Enterprisewide License \$4499.00

Report description:

The global peptide therapeutics market size reached US\$ 39.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 66.1 Billion by 2028, exhibiting a growth rate (CAGR) of 9.10% during 2022-2028.

Peptides are efficacious and selective signaling molecules that bind to specific cell surface receptors, such as ion channels and G protein-coupled receptors (GPCRs) and trigger intracellular effects. They are employed in the pharmaceutical industry to design novel regenerative therapeutics that can target a wide range of cells and manipulate their responses. These therapeutics are less toxic, relatively safe, and well-tolerated than other treatment options. As a result, they are gaining traction in clinical practices worldwide to manage cancer, injuries, infectious diseases, metabolic disorders, and aesthetic concerns.

Peptide Therapeutics Market Trends:

The growing prevalence of acute and chronic diseases, along with the rising access to medical facilities, represents one of the leading factors positively influencing the demand for peptides to develop innovative therapies. Moreover, peptides therapies are used in cosmeceutical surgeries to slow down the process of skin aging. This, coupled with the increasing consciousness among

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

individuals about physical appearance and the desire to retain young and healthy skin, is driving the adoption of cosmetic surgeries and peptide therapeutics around the world. Apart from this, with the introduction of novel synthetic strategies that reduce injection frequency and improve stability and other physical properties, peptide therapeutics are widely being used in injections for diabetic patients. This, in confluence with the increasing incidence of diabetes and the growing preference for quick and precise treatment methods, is influencing the use of peptide therapeutics over oral medications. Furthermore, the emerging trend of personalized and targeted treatments is catalyzing the demand for multifunctional peptide-based materials. This, along with the rising funding to develop novel peptide therapeutics for treating autoimmune and inflammatory diseases, is projected to create a positive market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global peptide therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, type of manufacturer, synthesis technology, routes of administration and application.

Breakup by Type:

- Innovative
- Generic

Breakup by Type of Manufacturer:

- Outsourced
- In-house

Breakup by Synthesis Technology:

- Solid Phase Peptide Synthesis
- Liquid Phase Peptide Synthesis
- Hybrid Technology

Breakup by Routes of Administration:

- Parenteral
- Oral
- Others

Breakup by Application:

- Gastrointestinal Disorders
- Neurological Disorders
- Metabolic Disorders
- Cancer
- Others

Breakup by Region:

- North America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Apitope International NV, Arch Biopartners Inc., AstraZeneca plc, Circle Pharma Inc., Corden Pharma GmbH, F. Hoffmann-La Roche AG, Ipsen Group, Lonza Group AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Industries Ltd. and Zealand Pharma A/S.

Key Questions Answered in This Report

1. How big is the global peptide therapeutics market?
2. What is the expected growth rate of the global peptide therapeutics market during 2023-2028?
3. What are the key factors driving the global peptide therapeutics market?
4. What has been the impact of COVID-19 on the global peptide therapeutics market?
5. What is the breakup of the global peptide therapeutics market based on the type?
6. What is the breakup of the global peptide therapeutics market based on the type of manufacturer?
7. What is the breakup of the global peptide therapeutics market based on the synthesis technology?
8. What is the breakup of the global peptide therapeutics market based on the routes of administration?
9. What is the breakup of the global peptide therapeutics market based on the application?
10. What are the key regions in the global peptide therapeutics market?
11. Who are the key players/companies in the global peptide therapeutics market?

Table of Contents:

- 1 Preface
- 2 Scope and Methodology
 - 2.1 Objectives of the Study
 - 2.2 Stakeholders

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
 - 4.1 Overview
 - 4.2 Key Industry Trends
- 5 Global Peptide Therapeutics Market
 - 5.1 Market Overview
 - 5.2 Market Performance
 - 5.3 Impact of COVID-19
 - 5.4 Market Forecast
- 6 Market Breakup by Type
 - 6.1 Innovative
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
 - 6.2 Generic
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 7 Market Breakup by Type of Manufacturer
 - 7.1 Outsourced
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
 - 7.2 In-house
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
- 8 Market Breakup by Synthesis Technology
 - 8.1 Solid Phase Peptide Synthesis
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
 - 8.2 Liquid Phase Peptide Synthesis
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
 - 8.3 Hybrid Technology
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast
- 9 Market Breakup by Routes of Administration
 - 9.1 Parenteral
 - 9.1.1 Market Trends
 - 9.1.2 Market Forecast
 - 9.2 Oral
 - 9.2.1 Market Trends
 - 9.2.2 Market Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3 Others
 - 9.3.1 Market Trends
 - 9.3.2 Market Forecast
- 10 Market Breakup by Application
 - 10.1 Gastrointestinal Disorders
 - 10.1.1 Market Trends
 - 10.1.2 Market Forecast
 - 10.2 Neurological Disorders
 - 10.2.1 Market Trends
 - 10.2.2 Market Forecast
 - 10.3 Metabolic Disorders
 - 10.3.1 Market Trends
 - 10.3.2 Market Forecast
 - 10.4 Cancer
 - 10.4.1 Market Trends
 - 10.4.2 Market Forecast
 - 10.5 Others
 - 10.5.1 Market Trends
 - 10.5.2 Market Forecast
- 11 Market Breakup by Region
 - 11.1 North America
 - 11.1.1 United States
 - 11.1.1.1 Market Trends
 - 11.1.1.2 Market Forecast
 - 11.1.2 Canada
 - 11.1.2.1 Market Trends
 - 11.1.2.2 Market Forecast
 - 11.2 Asia-Pacific
 - 11.2.1 China
 - 11.2.1.1 Market Trends
 - 11.2.1.2 Market Forecast
 - 11.2.2 Japan
 - 11.2.2.1 Market Trends
 - 11.2.2.2 Market Forecast
 - 11.2.3 India
 - 11.2.3.1 Market Trends
 - 11.2.3.2 Market Forecast
 - 11.2.4 South Korea
 - 11.2.4.1 Market Trends
 - 11.2.4.2 Market Forecast
 - 11.2.5 Australia
 - 11.2.5.1 Market Trends
 - 11.2.5.2 Market Forecast
 - 11.2.6 Indonesia
 - 11.2.6.1 Market Trends
 - 11.2.6.2 Market Forecast
 - 11.2.7 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.7.1 Market Trends
 - 11.2.7.2 Market Forecast
- 11.3 Europe
 - 11.3.1 Germany
 - 11.3.1.1 Market Trends
 - 11.3.1.2 Market Forecast
 - 11.3.2 France
 - 11.3.2.1 Market Trends
 - 11.3.2.2 Market Forecast
 - 11.3.3 United Kingdom
 - 11.3.3.1 Market Trends
 - 11.3.3.2 Market Forecast
 - 11.3.4 Italy
 - 11.3.4.1 Market Trends
 - 11.3.4.2 Market Forecast
 - 11.3.5 Spain
 - 11.3.5.1 Market Trends
 - 11.3.5.2 Market Forecast
 - 11.3.6 Russia
 - 11.3.6.1 Market Trends
 - 11.3.6.2 Market Forecast
 - 11.3.7 Others
 - 11.3.7.1 Market Trends
 - 11.3.7.2 Market Forecast
- 11.4 Latin America
 - 11.4.1 Brazil
 - 11.4.1.1 Market Trends
 - 11.4.1.2 Market Forecast
 - 11.4.2 Mexico
 - 11.4.2.1 Market Trends
 - 11.4.2.2 Market Forecast
 - 11.4.3 Others
 - 11.4.3.1 Market Trends
 - 11.4.3.2 Market Forecast
- 11.5 Middle East and Africa
 - 11.5.1 Market Trends
 - 11.5.2 Market Breakup by Country
 - 11.5.3 Market Forecast
- 12 SWOT Analysis
 - 12.1 Overview
 - 12.2 Strengths
 - 12.3 Weaknesses
 - 12.4 Opportunities
 - 12.5 Threats
- 13 Value Chain Analysis
- 14 Porters Five Forces Analysis
 - 14.1 Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
- 15 Price Analysis
- 16 Competitive Landscape
 - 16.1 Market Structure
 - 16.2 Key Players
 - 16.3 Profiles of Key Players
 - 16.3.1 Amgen Inc.
 - 16.3.1.1 Company Overview
 - 16.3.1.2 Product Portfolio
 - 16.3.1.3 Financials
 - 16.3.1.4 SWOT Analysis
 - 16.3.2 Apitope International NV
 - 16.3.2.1 Company Overview
 - 16.3.2.2 Product Portfolio
 - 16.3.3 Arch Biopartners Inc.
 - 16.3.3.1 Company Overview
 - 16.3.3.2 Product Portfolio
 - 16.3.3.3 Financials
 - 16.3.4 AstraZeneca plc
 - 16.3.4.1 Company Overview
 - 16.3.4.2 Product Portfolio
 - 16.3.4.3 Financials
 - 16.3.4.4 SWOT Analysis
 - 16.3.5 Circle Pharma Inc.
 - 16.3.5.1 Company Overview
 - 16.3.5.2 Product Portfolio
 - 16.3.6 Corden Pharma GmbH
 - 16.3.6.1 Company Overview
 - 16.3.6.2 Product Portfolio
 - 16.3.7 F. Hoffmann-La Roche AG
 - 16.3.7.1 Company Overview
 - 16.3.7.2 Product Portfolio
 - 16.3.7.3 SWOT Analysis
 - 16.3.8 Ipsen Group
 - 16.3.8.1 Company Overview
 - 16.3.8.2 Product Portfolio
 - 16.3.8.3 Financials
 - 16.3.8.4 SWOT Analysis
 - 16.3.9 Lonza Group AG
 - 16.3.9.1 Company Overview
 - 16.3.9.2 Product Portfolio
 - 16.3.9.3 Financials
 - 16.3.9.4 SWOT Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.3.10 Novo Nordisk A/S
 - 16.3.10.1 Company Overview
 - 16.3.10.2 Product Portfolio
 - 16.3.10.3 Financials
 - 16.3.10.4 SWOT Analysis
- 16.3.11 Pfizer Inc.
 - 16.3.11.1 Company Overview
 - 16.3.11.2 Product Portfolio
 - 16.3.11.3 Financials
 - 16.3.11.4 SWOT Analysis
- 16.3.12 Teva Pharmaceuticals Industries Ltd.
 - 16.3.12.1 Company Overview
 - 16.3.12.2 Product Portfolio
 - 16.3.12.3 Financials
 - 16.3.12.4 SWOT Analysis
- 16.3.13 Zealand Pharma A/S
 - 16.3.13.1 Company Overview
 - 16.3.13.2 Product Portfolio
 - 16.3.13.3 Financials

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Peptide Therapeutics Market Report by Type (Innovative, Generic), Type of Manufacturer (Outsourced, In-House), Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, Hybrid Technology), Routes of Administration (Parenteral, Oral, and Others), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Others), and Region 2023-2028

Market Report | 2023-11-24 | 149 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$2499.00
	Five User Licence	\$3499.00
	Enterprisewide License	\$4499.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-23"/>
		Signature	<div><div></div></div>